Motley Fool Australia

Mesoblast Ltd (ASX: MSB) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover
As at

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $2.42 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 585.80 million
Earnings per share -3.257
Dividend per share N/A
Year To Date Return 95.67%
Earnings Yield N/A
Franking N/A

Mesoblast Limited (ASX: MSB) Latest News

jump in asx share price represented by man jumping in the air in celebration

The Mesoblast (ASX:MSB) share price jumped 33% in November and could go even higher

More »

ASX 200

ASX 200 flat on Wednesday

More »

hand on touch screen lit up by a share price chart moving higher

Why Laybuy, Mesoblast, Sandfire, & Telix shares are charging higher

More »

Worried young male investor watches financial charts on computer screen

ASX 200 down 0.2%: Zip’s November update, Mesoblast jumps, Westpac’s asset sale

More »

Mesoblast (ASX:MSB) share price jumps 19% on FDA update

More »

Flight Centre and Mesoblast were among the most traded shares on the ASX last week

More »

pills spilling from bottle

2 ASX 200 healthcare shares that outperformed in November 

More »

investor looking excited at rising asx 200 share price on laptop

ASX 200 Weekly Wrap: ASX 200 on track for a top month

More »

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size
 

About Mesoblast Ltd (ASX: MSB)

Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Dec 2020 $4.13 $-0.03 -0.72% 2,597,535 $4.18 $4.22 $4.09
30 Nov 2020 $4.16 $0.09 2.21% 3,761,674 $4.10 $4.25 $4.09
27 Nov 2020 $4.07 $-0.02 -0.49% 3,034,144 $4.04 $4.12 $4.02
26 Nov 2020 $4.09 $-0.06 -1.45% 5,507,824 $4.13 $4.31 $4.00
25 Nov 2020 $4.15 $-0.32 -7.16% 8,056,804 $4.55 $4.62 $4.13
24 Nov 2020 $4.47 $0.19 4.44% 19,344,460 $4.48 $5.05 $4.41
23 Nov 2020 $4.28 $0.64 17.58% 18,565,596 $3.74 $4.29 $3.69
20 Nov 2020 $3.64 $0.37 11.31% 17,154,614 $3.80 $3.95 $3.60
19 Nov 2020 $3.27 $0.02 0.62% 2,240,982 $3.25 $3.29 $3.23
18 Nov 2020 $3.25 $0.00 0.00% 2,120,127 $3.28 $3.30 $3.25
17 Nov 2020 $3.25 $-0.08 -2.40% 2,260,357 $3.30 $3.33 $3.25
16 Nov 2020 $3.33 $0.08 2.46% 494,977 $3.26 $3.35 $3.26
13 Nov 2020 $3.25 $0.05 1.56% 2,424,021 $3.21 $3.26 $3.19
12 Nov 2020 $3.20 $-0.08 -2.44% 2,390,685 $3.28 $3.29 $3.20
11 Nov 2020 $3.28 $0.15 4.79% 5,828,719 $3.22 $3.36 $3.19
10 Nov 2020 $3.13 $-0.25 -7.40% 6,269,799 $3.21 $3.24 $3.13
09 Nov 2020 $3.38 $0.18 5.63% 4,287,118 $3.24 $3.38 $3.24
06 Nov 2020 $3.20 $-0.05 -1.54% 2,428,259 $3.26 $3.29 $3.20
05 Nov 2020 $3.25 $0.07 2.20% 3,445,442 $3.20 $3.25 $3.15
04 Nov 2020 $3.18 $0.05 1.60% 3,089,629 $3.18 $3.23 $3.11
03 Nov 2020 $3.13 $0.08 2.62% 2,127,938 $3.07 $3.16 $3.06
Show more

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
24 Jun 2020 Silviu Itescu Issued 1 $6,542,108
24 Jun 2020 Eric Rose Expiry 80 $277,600
24 Jun 2020 Eric Rose Issued 100 $347,000
24 Jun 2020 William (Bill) Burns Expiry 80 $277,600
24 Jun 2020 William (Bill) Burns Issued 100 $347,000
24 Jun 2020 Joseph Swedish Issued 300 $1,041,000
18 Mar 2020 Donal O'Dwyer Buy 85 $100,297
18 Mar 2020 Donal O'Dwyer Transfer 811 $933,597
18 Mar 2020 Donal O'Dwyer Transfer 811 $933,597
03 Dec 2019 William (Bill) Burns Buy 32 $59,786
Show more


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Michael Robert Spooner Non-Executive Director Sep 2004
Professor Silviu Itescu Chief Executive Officer,Executive Director Jun 2004
Mr Donal Paul O'Dwyer Non-Executive Director Sep 2004
Dr Eric A Rose Non-Executive Director Apr 2013
Mr William (Bill) A Burns Non-Executive Director,Vice-Chairman Mar 2014
Mr Joseph R Swedish Non-Executive Director,Non-Executive Chairman Jun 2018
Ms Shawn Cline Tomasello Non-Executive Director Jul 2018
Mr Charlie Harrison Company Secretary Sep 2014
Ms Niva Sivakumar Joint Company Secretary Oct 2019
Josh Muntner Chief Financial Officer
Fred Grossman Chief Medical Officer
Dagmar Rosa-Bjorkeson Chief Operating Officer
Charlie Harrison Company Secretary
Peter Howard General Counsel
John McMannis Head of Manufacturing
Geraldine Storton Head of Regulatory Affairs and Quality Management
Paul Simmons Head of Research and New Product Development
Niva Sivakumar Joint Company Secretary
Eric Strati Pharma Partnering
Michael Schuster Pharma Partnering
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 107,438,069 18.32%
HSBC Custody Nominees (Australia) Limited 103,290,771 17.61%
Professor Silviu Itescu 67,751,838 11.55%
Citicorp Nominees Pty Limited 13,318,990 2.27%
UBS Nominees Pty Ltd 11,101,280 1.89%
National Nominees Limited 10,653,027 1.82%
Independent Asset Management Pty Limited 7,870,558 1.34%
BNP Paribas Nominees Pty Ltd 6,203,700 1.06%
Merrill Lynch (Australia) Nominees Pty Limited 6,084,737 1.04%
BNP Paribas Nominees Pty Ltd i 4,986,283 0.85%
Dalit Pty Ltd 4,828,839 0.82%
Mr Gregory John Matthews & Mrs Janine Marie Matthews 3,956,219 0.67%
CA Third Nominees Pty Limited 3,832,425 0.65%
Dalit Pty Ltd i 2,195,000 0.37%
Citicorp Nominees Pty Limited i 2,077,360 0.35%
Kentgrove Capital Pty Ltd 2,000,100 0.34%
BNP Paribas Noms Pty Ltd 1,908,014 0.33%
HSBC Custody Nominees (Australia) Limited Gsco Eca 1,784,018 0.30%
LALP Pty Ltd 1,647,144 0.28%
BNP Paribas Nominees Pty Ltd ii 1,645,043 0.28%
Show more